Both the AstraZeneca and Johnson & Johnson COVID-19 vaccines have regulatory warnings about vaccine-induced immune thrombotic thrombocytopeni (VITT) now, and data have shown that women under 60 years old appear to be at a higher risk. Symptoms include intracranial pressure, shortness of breath, lethargy, back pain, abdominal pain, spot bleeding under the skin, and leg or arm weakness, as well as positive test results for heparin-induced thrombocytopenia (HIT). Onset occurs a median of 8 or 10 days after receiving the Johnson & Johnson or AstraZeneca COVID-19 vaccine, respectively.
CVST, one of the worst manifestations of VITT, happens when clots form in the brain and major dural sinuses. While the average 30-day mortality is 6%, about 10% of patients have permanent neurological issues 1 year later.
Studies look at clotting, myocarditis tied to COVID-19 vaccines | CIDRAP (umn.edu)
I got the J&J mid-March. So far no problems but I”m worried about the spike protein clogging up my capillaries.
The warning about VITT has been known for months, yet, they allowed these vaccines to be given.
Out of 14 million doses of J&J administered in the USA so far, how many cases of VITT have been reported?
I use Plavix, Pine Bark Extract, aspirin and lots of water to deal with VITT